Cargando…
Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
AIMS: To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults without diabetes. MATERIALS AND METHODS: In this single‐centre, double‐blind trial, we randomized 50 obese adults with...
Autores principales: | Lundkvist, Per, Sjöström, C. David, Amini, Sam, Pereira, Maria J., Johnsson, Eva, Eriksson, Jan W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215525/ https://www.ncbi.nlm.nih.gov/pubmed/27550386 http://dx.doi.org/10.1111/dom.12779 |
Ejemplares similares
-
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
por: Lundkvist, Per, et al.
Publicado: (2017) -
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
por: Pereira, Maria J., et al.
Publicado: (2018) -
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017) -
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018) -
Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)